// App-Quantinova.ai

7029 : Efficacy and safety of inotuzumab ozogamicin (InO) in older patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) enrolled in the phase 3 INO-VATE trial.

Researchers

Presenter

  • Elias Jabbour

Principal Investigators

  • Anjali S. Advani

  • Matthias Stelljes

  • Wendy Stock

  • Michaela Liedtke

  • Nicola Gokbuget

  • Giovanni Martinelli

  • Susan Mary O'Brien

  • Kongming Wang

  • Tao Wang

  • M. Luisa Paccagnella

  • Barbara Sleight

  • Erik Vandendries

  • Daniel J. DeAngelo

  • Hagop M Kantarjian

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland, OH

  • Universitatsklinikum Munster, Munster, Germany

  • The University of Chicago Medical Center, Chicago, IL

  • Stanford School of Medicine, Stanford, CA

  • Goethe University, Frankfurt, Germany

  • Institute Seragnoli, DIMES, University of Bologna, Bologna, Italy

  • University of California, Irvine, Fullerton, CA

  • Pfizer Inc, Oncology, Pearl River, NY

  • Pfizer Oncology, Groton, CT

  • Pfizer Oncology, Cambridge, MA

  • Dana-Farber Cancer Institute, Boston, MA

  • The University of Texas MD Anderson Cancer Center, Department of Neurosurgery, Houston, TX

Locations

  • United States

  • Germany

  • Italy

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Inotuzumab ozogamicin

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT01564784

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved